Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
Taikonaut Sparks Enthusiasm for Space As China Celebrates Its Space DayMoxibustion Treatment Picking up During Heat WavesVillage Basketball Competition Kicks off in SW China's GuizhouWater festival attacks kill 3 during Myanmar coup leader’s holiday — Radio Free AsiaChina's Annual Vocational Education Week Opens in ShandongChina to Implement Garbage Sorting in All Cities by 2025CCTF, Tencent Launch Special Fund to Build Girl's ChorusesChina Makes Great Progress in Combating Trafficking in Women and Children: ExpertTourism Booms Across China As 5Water festival attacks kill 3 during Myanmar coup leader’s holiday — Radio Free Asia